CoChat

Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities

Open access

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Significance: Immune checkpoint therapies have garnered significant attention due to their ability to induce dramatic clinical responses in patients with various solid tumor malignancies, including prostate cancer. However, these therapeutic agents often elicit immune-related adverse events (irAEs) that may result in substantial morbidity. Early intervention can markedly reduce the severity of the irAEs, but biomarkers that allow for their early detection and guide their management are lacking. Based on peripheral blood samples collected longitudinally in two prostate cancer clinical trials, we propose CD8 T-cell clonal expansion within the systemic circulation as a potential correlative biomarker of immune-related adverse events that occur with ipilimumab therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1611421113

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 226

Metadata

Authors
Subudhi, S. K., Aparicio, A., Gao, J., Zurita, A. J., Araujo, J. C., Logothetis, C. J., Tahir, S. A., Korivi, B. R., Slack, R. S., Vence, L., Emerson, R. O., Yusko, E., Vignali, M., Robins, H. S., Sun, J., Allison, J. P., & Sharma, P.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Adaptive Biotechnologies (United States) (US)
  • Fred Hutch Cancer Center (US)
Venue
Proceedings of the National Academy of Sciences
Published
2016-10-03
Volume
113
Issue
42
Pages
11919-11924
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2529299484
Cited by
226
References
32
Citations by year
2026: 8 · 2025: 19 · 2024: 16 · 2023: 25 · 2022: 39 · 2021: 35 · 2020: 30 · 2019: 18 · 2018: 22 · 2017: 13
FWCI
9.51
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Cancer Prevention and Research Institute of Texas (RP120108)
  • HHS | NIH | National Cancer Institute (CA1633793, CA088084, P30CA016672)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
ipilimumab, immune-related adverse events, CD8+ T cells, T cell clonal expansion, immune checkpoint inhibitors, metastatic prostate cancer, androgen deprivation therapy, biomarkers
MeSH terms
Antineoplastic Agents, Immunological, Ipilimumab, Antineoplastic Combined Chemotherapy Protocols, Disease Susceptibility, Humans, Male, Middle Aged, Prostatic Neoplasms, Severity of Illness Index, Biomarkers, T-Lymphocyte Subsets, Treatment Outcome, Clinical Trials, Phase II as Topic, CD8-Positive T-Lymphocytes, Lymphocyte Count, Clonal Evolution, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. https://app.cochat.ai/papers/10.1073/pnas.1611421113
The paper
Subudhi, S. K., Aparicio, A., Gao, J., Zurita, A. J., Araujo, J. C., Logothetis, C. J., Tahir, S. A., Korivi, B. R., Slack, R. S., Vence, L., Emerson, R. O., Yusko, E., Vignali, M., Robins, H. S., Sun, J., Allison, J. P., & Sharma, P. (2016). Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1611421113

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.